A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia

被引:72
作者
Chengappa, K. N. Roy [1 ]
Turkin, Scott R. [2 ]
DeSanti, Susan [3 ]
Bowie, Christopher R. [4 ]
Brar, Jaspreet S.
Schlicht, Patricia J.
Murphy, Sherry L. [2 ]
Hetrick, Michelle L. [2 ]
Bilder, Robert [5 ]
Fleet, David [6 ]
机构
[1] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Comprehens Recovery Serv,Sch Med, Pittsburgh, PA 15213 USA
[2] Dubois Reg Med Ctr, Du Bois, PA USA
[3] NYU, Dept Psychiat, Langone Med Ctr New York, New York, NY 10003 USA
[4] Queens Univ, Kingston, ON, Canada
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Datamagik, London, England
关键词
L-carnosine; Cognition; Schizophrenia; Randomized clinical trial; Set shifting; Perseverative errors; SET-SHIFTING ABILITY; EPISODE SCHIZOPHRENIA; EXECUTIVE FUNCTION; CEREBRAL-ISCHEMIA; MENTALLY-ILL; GLUTAMATE; HISTIDINE; RECEPTORS; PROTECTS; CELLS;
D O I
10.1016/j.schres.2012.10.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Targeting glutamatergic dysfunction provides an exciting opportunity to improve cognitive impairment in schizophrenia. One treatment approach has targeted inadequate antioxidant defenses at glutamatergic synapses. Animal and human data suggest NMDA antagonists worsen executive cognitive controls - e.g. increase perseverative responses and impair set-shifting. We conducted a preliminary study to test the hypothesis that L-carnosine, an antioxidant and anti-glycation agent which is co-localized and released with glutamate would improve executive dysfunction, a cognitive domain associated with glutamate. Methods: Seventy-five symptomatically stable adults with chronic schizophrenia were randomly assigned to L-carnosine as adjunctive treatment (2 g/day) or amatched placebo in a double-blindmanner for 3 months. Cognitive domains (executive dysfunction, memory, attention and motor speed) were assessed using a computerized battery at baseline, 4 and 12 weeks, along with psychopathology ratings and safety parameters. Results: The L-carnosine group performed significantly faster on non-reversal condition trials of the set-shifting test compared with placebo but reversal reaction times and errors were not significantly different between treatments. On the strategic target detection test, the L-carnosine group displayed significantly improved strategic efficiency and made fewer perseverative errors compared with placebo. Other cognitive tests showed no significant differences between treatments. Psychopathology scores remained stable. The carnosine group reported more adverse events (30%) compared with the placebo group (14%). Laboratory indices remained within acceptable ranges. Conclusions: These preliminary findings suggest that L-carnosine merits further consideration as adjunctive treatment to improve executive dysfunction in persons with schizophrenia. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 68 条
  • [1] A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS
    ADDINGTON, D
    ADDINGTON, J
    SCHISSEL, B
    [J]. SCHIZOPHRENIA RESEARCH, 1990, 3 (04) : 247 - 251
  • [2] [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
  • [3] Enhanced Carbonyl Stress in a Subpopulation of Schizophrenia
    Arai, Makoto
    Yuzawa, Hiroko
    Nohara, Izumi
    Ohnishi, Tetsuo
    Obata, Nanako
    Iwayama, Yoshimi
    Haga, Seiichi
    Toyota, Tomoko
    Ujike, Hiroshi
    Arai, Mayumi
    Ichikawa, Tomoe
    Nishida, Atsushi
    Tanaka, Yoko
    Furukawa, Aizo
    Aikawa, Yuuzou
    Kuroda, Osamu
    Niizato, Kazuhiro
    Izawa, Ryosuke
    Nakamura, Kazuhiko
    Mori, Norio
    Matsuzawa, Daisuke
    Hashimoto, Kenji
    Iyo, Masaomi
    Sora, Ichiro
    Matsushita, Masaaki
    Okazaki, Yuji
    Yoshikawa, Takeo
    Miyata, Toshio
    Itokawa, Masanari
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (06) : 589 - 597
  • [4] Bakardjiev A, 1998, GLIA, V24, P346, DOI 10.1002/(SICI)1098-1136(199811)24:3<346::AID-GLIA9>3.3.CO
  • [5] 2-R
  • [6] Barua P., 2001, SCHIZOPHR B, V31, P318
  • [7] N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
    Berk, Michael
    Copolov, David
    Dean, Olivia
    Lu, Kristy
    Jeavons, Sue
    Schapkaitz, Ian
    Anderson-Hunt, Murray
    Judd, Fiona
    Katz, Fiona
    Katz, Paul
    Ording-Jespersen, Sean
    Little, John
    Conus, Philippe
    Cuenod, Michel
    Do, Kim Q.
    Bush, Ashley I.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 64 (05) : 361 - 368
  • [8] Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free radicals
    Boldyrev, AA
    Stvolinsky, SL
    Tyulina, OV
    Koshelev, VB
    Hori, N
    Carpenter, DO
    [J]. CELLULAR AND MOLECULAR NEUROBIOLOGY, 1997, 17 (02) : 259 - 271
  • [9] Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures
    Bowie, Christopher R.
    Leung, Winnie W.
    Reichenberg, Abraham
    McClure, Margaret M.
    Patterson, Thomas L.
    Heaton, Robert K.
    Harvey, Philip D.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (05) : 505 - 511
  • [10] Self-assessment of functional status in schizophrenia
    Bowie, Christopher R.
    Twamley, Elizabeth W.
    Anderson, Hannah
    Halpern, Brooke
    Patterson, Thomas L.
    Harvey, Philip D.
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2007, 41 (12) : 1012 - 1018